thiosulfates has been researched along with Mesothelioma in 6 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with malignant mesothelioma were treated with an experimental intracavitary chemotherapy regimen of weekly intraperitoneal or intrapleural cisplatin (90-100 mg/m2) with simultaneous intravenous sodium thiosulfate delivered to protect against cisplatin-induced nephrotoxicity." | 3.67 | Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. ( Cleary, S; Howell, SB; Markman, M; Pfeifle, C, 1986) |
| " This pilot study demonstrates a pharmacokinetic advantage of ip chemotherapy with c-DDP and an effectiveness against peritoneal carcinosis." | 1.27 | [Therapy of peritoneal carcinosis with intraperitoneal administration of cis-diamminedichloroplatinum and systemic sodium thiosulfate protection. Clinical results of a pilot study and pharmacokinetics]. ( Ehninger, G; Haag, C; Rückle, H; Wilms, K, 1985) |
| "Sodium thiosulfate has been shown experimentally to protect against cisplatin-induced renal insufficiency by inactivating the nephrotoxic as well as cytotoxic properties of the agent." | 1.27 | Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. ( Cleary, S; Howell, SB; Markman, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MY | 1 |
| Sugarbaker, DJ | 1 |
| Markman, M | 4 |
| Cleary, S | 4 |
| Pfeifle, CE | 1 |
| Howell, SB | 4 |
| Pfeifle, C | 1 |
| Ehninger, G | 1 |
| Rückle, H | 1 |
| Haag, C | 1 |
| Wilms, K | 1 |
1 review available for thiosulfates and Mesothelioma
| Article | Year |
|---|---|
Innovative therapies: intraoperative intracavitary chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase I as Topic; Humans; Hyperthermia, Induced; | 2004 |
5 other studies available for thiosulfates and Mesothelioma
| Article | Year |
|---|---|
High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Ear Diseases; Fe | 1985 |
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelli | 1986 |
Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
Topics: Adult; Aged; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases | 1986 |
[Therapy of peritoneal carcinosis with intraperitoneal administration of cis-diamminedichloroplatinum and systemic sodium thiosulfate protection. Clinical results of a pilot study and pharmacokinetics].
Topics: Adenocarcinoma; Ascites; Carcinoma; Catheterization; Cisplatin; Female; Humans; Kinetics; Male; Meso | 1985 |
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.
Topics: Acute Kidney Injury; Adult; Aged; Cisplatin; Creatinine; Female; Humans; Injections; Injections, Int | 1985 |